Fig. 2

Plasma CXCL9, CXCL10, and CXCL11 levels during PHI were correlated with viral load. a Analysis of correlations between plasma CXCL9 (r = 0.2764, p = 0.0496), CXCL10 (r = 0.4055, p = 0.0032), and CXCL11 (r = 0.219, p = 0.1225) levels in HIV⁺ samples and VL at the same sampling point (n = 51). b Comparisons of CXCL9, CXCL10, and CXCL11 levels between VL-high (n = 33) and VL-low (n = 18) groups at the sampling point (CXCL9, p = 0.0381; CXCL10, p = 0.0079; CXCL11, p = 0.1161). c Analysis of the correlations between plasma CXCL9 (r = 0.2963, p = 0.0793), CXCL10 (r = 0.3058, p = 0.0697), and CXCL11 (r = 0.134, p = 0.4359) levels at the HIV⁺ point and VL at set-point (n = 35). d Comparisons of CXCL9, CXCL10, and CXCL11 levels between the VL-high (n = 24) and VL-low (n = 11) groups at set-point (CXCL9, p = 0.0035; CXCL10, p = 0.0052; CXCL11, p = 0.0896). Spearman correlation analysis was used to estimate the level of correlation. A nonparametric Mann–Whitney U test was used to compare between-group distributions; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001